Back

Formate reduces ischemic injury in the male heart by increasing protein S-nitrosation

Garbus-Grant, H.; Kabir, R.; Ebenebe, O. V.; Patel, P.; Ashok, D.; Quiroga, D.; Das, S.; O'Rourke, B.; Crabtree, M.; Kohr, M. J.

2026-02-26 physiology
10.64898/2026.02.24.707768 bioRxiv
Show abstract

Ischemic heart disease is a leading cause of death for both men and women in the United States. We and others have demonstrated that nitric oxide (NO) signaling and associated protein S-nitrosation (SNO) play a key role in reducing ischemic injury in the heart. We also find that while females typically exhibit endogenous protection from ischemic injury, this protection is abrogated with the loss of the formate-generating enzyme alcohol dehydrogenase 5 (ADH5), but formate supplementation provided a rescue. Here, we investigate the cardioprotective efficacy of formate in male hearts. Hearts were Langendorff-perfused and subjected to ischemia/reperfusion (I/R) injury with and without formate. Formate-mediated protection was also examined using an in vitro model of coverslip-induced ischemic injury to identify molecular underpinnings. We found that formate yields protection from I/R injury in ex vivo and in vitro models by increasing post-ischemic protein SNO levels, while NO synthase inhibition blocked this formate-mediated increase in protein SNO in vitro, and attenuated protection from I/R injury ex vivo. Moreover, post-ischemic levels of tetrahydrobiopterin (BH4), a cofactor necessary for NOS function, were preserved in formate-treated hearts. Furthermore, inhibition of dihydrofolate reductase (DHFR), a one-carbon enzyme critical for BH4 recycling, blunted formate-mediated protection ex vivo. Collectively, our findings suggest that formate is a potent cardioprotective agent that confers protection by preserving post-ischemic BH4 levels, and enhancing protein SNO levels through a NOS-dependent mechanism. These findings have significant implications for the clinical prevention and treatment of ischemic heart disease in males.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Circulation
66 papers in training set
Top 0.1%
32.3%
2
Circulation Research
39 papers in training set
Top 0.1%
18.2%
50% of probability mass above
3
Cell Reports
1338 papers in training set
Top 3%
9.9%
4
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.3%
3.6%
5
Journal of the American Heart Association
119 papers in training set
Top 2%
3.5%
6
eLife
5422 papers in training set
Top 27%
3.5%
7
Nature Communications
4913 papers in training set
Top 45%
2.4%
8
Nature Cardiovascular Research
28 papers in training set
Top 0.2%
2.1%
9
Molecular Metabolism
105 papers in training set
Top 0.8%
2.0%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 31%
1.7%
11
Cardiovascular Research
33 papers in training set
Top 0.5%
1.7%
12
Science
429 papers in training set
Top 15%
1.6%
13
American Journal of Physiology-Heart and Circulatory Physiology
32 papers in training set
Top 0.7%
1.5%
14
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.6%
1.2%
15
Function
15 papers in training set
Top 0.3%
1.2%
16
Science Advances
1098 papers in training set
Top 29%
0.8%
17
JACC: Basic to Translational Science
15 papers in training set
Top 0.5%
0.7%
18
Journal of the American College of Cardiology
12 papers in training set
Top 0.7%
0.7%
19
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.6%
20
Science Translational Medicine
111 papers in training set
Top 7%
0.6%
21
Hypertension
32 papers in training set
Top 0.9%
0.6%